Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia:: Report from the SENTRY Antimicrobial Surveillance Program (1998)

被引:26
作者
DiPersio, JR
Jones, RN
Barrett, T
Doern, GV
Pfaller, MA
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA
[2] Akron City Hosp, Summa Hlth Syst, Akron, OH USA
关键词
D O I
10.1016/S0732-8893(98)00083-2
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fluoroquinolone resistance in Moraxella catarrhalis isolates has been quite rare. This report presents a case history of a 22-year-old man with compromised immune status and severe pneumonia caused by M. catarrhalis. The organism was markedly resistant (MICs, 1.5-->32 mu g/mL) to several marketed fluoroquinolones including the agent (levofloxacin) used for concurrent and prior therapy. The emergence of this problematic strain seems related to chronic exposure of the patient to compounds in the class and poor patient compliance to prescribed medications. The strain was not clonally related to other M. catarrhalis strains isolated in the same hospital during early 1998. This second documented case of a fluoroquinolone-resistant M. catarrhalis clinical isolate presents a warning that resistances can emerge in at-risk patients, and that surveillance systems (SENTRY) will be necessary to monitor for unusual organisms and spread of resistance phenotypes among commonly isolated respiratory tract pathogens. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:131 / 135
页数:5
相关论文
共 21 条
[1]  
[Anonymous], 1988, PROGR ABSTR 28 INT C
[2]   IN-VITRO ACTIVITIES OF 12 ORALLY-ADMINISTERED ANTIMICROBIAL AGENTS AGAINST 4 SPECIES OF BACTERIAL RESPIRATORY PATHOGENS FROM US-MEDICAL-CENTERS IN 1992 AND 1993 [J].
BARRY, AL ;
PFALLER, MA ;
FUCHS, PC ;
PACKER, RR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) :2419-2425
[3]   Colonization and infection with Moraxella catarrhalis in childhood [J].
Berner, R ;
Schumacher, RF ;
Brandis, M ;
Forster, J .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (06) :506-509
[4]   TETRACYCLINE AND ERYTHROMYCIN RESISTANCE AMONG CLINICAL ISOLATES OF BRANHAMELLA-CATARRHALIS [J].
BROWN, BA ;
WALLACE, RJ ;
FLANAGAN, CW ;
WILSON, RW ;
LUMAN, JI ;
REDDITT, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (09) :1631-1633
[5]   In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against and Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [J].
Brueggemann, AB ;
Kugler, KC ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1594-1597
[6]   LOWER RESPIRATORY-TRACT INFECTION DUE TO CIPROFLOXACIN RESISTANT MORAXELLA-CATARRHALIS [J].
CUNLIFFE, NA ;
EMMANUEL, FXS ;
THOMSON, CJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (01) :273-274
[7]  
DAVIES BI, 1988, EUR RESPIR J, V1, P415
[8]   Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: Results of a 30-center national surveillance study [J].
Doern, GV ;
Brueggemann, AB ;
Pierce, G ;
Hogan, T ;
Holley, HP ;
Rauch, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2884-2886
[9]   FLUOROQUINOLONE (LOMEFLOXACIN) INTERNATIONAL SURVEILLANCE TRIAL - A REPORT OF 30 MONTHS OF MONITORING INVITRO ACTIVITY [J].
JONES, RN .
AMERICAN JOURNAL OF MEDICINE, 1992, 92 :S52-S57
[10]  
JONES RN, 1997, P 37 ICAAC WASH DC A